Left ventricular hypertrophy, dilatation and ejection fractions predict ventricular tachycardia in amyloid transthyretin cardiomyopathy

FUNDING ACKNOWLEDGEMENTS: Type of funding sources: Private company. Main funding source(s): Pfizer Global Medical Grant BACKGROUND: Amyloid transthyretin cardiomyopathy (ATTR-CM) is a progressive infiltrative cardiomyopathy caused by extracellular deposition of amyloid fibrils. The disease is charac...

Descripción completa

Detalles Bibliográficos
Autores principales: Knoll, K, Fuchs, P, Weidmann, I, Gross, S, Altunkas, F, Lennerz, C, Kolb, C, Kessler, T, Schunkert, H, Hengstenberg, W, Trenkwalder, T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
13.2 - Epidemiology, Prognosis, Outcome
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207568/
http://dx.doi.org/10.1093/europace/euad122.274

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207568/
http://dx.doi.org/10.1093/europace/euad122.274

Ejemplares similares